Real Chemistry and Aktana Announce New Partnership
Partnership pairs Aktana’s Contextual Intelligence Engine with Real Chemistry’s data and creative campaign.
Real Chemistry, a global health innovation company, and Aktana, a pioneer in intelligent customer engagement for the global life sciences industry, today announced a partnership that will reimagine commercial strategy, engagement and execution. Pre-built integrations between the two companies’ solutions will translate Real Chemistry’s healthcare social data points from 3 million healthcare influencers and 160,000 healthcare providers (HCPs) and claims data into dynamic, actionable insights for life sciences sales, marketing and medical teams.
Through this partnership, life sciences companies will be equipped not only to identify the right HCPs, but also to predict the right engagement timing, content, channel, and next-best actions to help HCPs learn about new treatment options and improve patient care.
Read more about the new partnership here.
GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease
May 14th 2025Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
